Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help ...

Researchers at the University of Geneva have built a molecular system that can tell the difference between a cancer cell and ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype ...

We included 77 studies: 47 studies reported factors from clinicians' perspective, 33 studies reported patients' perspective, 23 studies reported implementation strategies, and seven studies evaluated ...

HOUSTON, APRIL 6, 2026 ― Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

Cancer treatment has long been haunted by the same problem: how do you strike dangerous cells without hitting healthy ones ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

For most patients diagnosed with kidney cancer, the standard playbook is clear. Immunotherapy and targeted therapies directed ...